APA (7th ed.) Citation

Marron, T., Misleh, J., chen, C., Wainberg, Z., Powderly, J., Boccia, R., . . . Spira, A. (2023). 1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors. Annals of Oncology, 34, S623. https://doi.org/10.1016/j.annonc.2023.09.2164

Chicago Style (17th ed.) Citation

Marron, T.U, et al. "1025MO Preliminary Safety, Pharmacokinetics and Immunomodulatory Activity of RBS2418, an Oral ENPP1 Inhibitor, Alone and in Combination with Pembrolizumab in Patients with Solid Tumors." Annals of Oncology 34 (2023): S623. https://doi.org/10.1016/j.annonc.2023.09.2164.

MLA (9th ed.) Citation

Marron, T.U, et al. "1025MO Preliminary Safety, Pharmacokinetics and Immunomodulatory Activity of RBS2418, an Oral ENPP1 Inhibitor, Alone and in Combination with Pembrolizumab in Patients with Solid Tumors." Annals of Oncology, vol. 34, 2023, p. S623, https://doi.org/10.1016/j.annonc.2023.09.2164.